Press Release
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
YolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Share
LATESTNEWS
-
YOLT-203 Receives Orphan Drug Designation from EMA
Jul 28, 2025
-
YolTech Therapeutics Announces NMPA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
Jul 14, 2025
-
Prof. Michael Ott Joins YolTech as Scientific Advisor
Jun 27, 2025
